Literature DB >> 25105946

Conventional risk factors and cardiovascular outcomes of patients with inflammatory bowel disease with confirmed coronary artery disease.

Ashish Aggarwal1, Ashish Atreja, Samir Kapadia, Rocio Lopez, Jean-Paul Achkar.   

Abstract

BACKGROUND: Inflammation is increasingly being recognized as an important factor in the pathogenesis of atherosclerosis and outcome of percutaneous coronary intervention (PCI). The purpose of this study was to compare conventional risk factors and PCI outcomes in patients with inflammatory bowel disease (IBD) and non-IBD controls with angiographically proven coronary artery disease (CAD).
METHODS: We performed a historical cohort study of patients with IBD who were diagnosed with CAD by cardiac catheterization between January 2004 and June 2010. Four non-IBD controls with CAD were matched to each IBD case. Framingham risk score and corresponding 10-year coronary heart disease risk were calculated for all the patients. Outcomes were obtained using a prospectively maintained Institutional Interventional Catheterization Database.
RESULTS: One hundred thirty-one patients with IBD (54 Crohn's disease, 77 ulcerative colitis) with CAD and 524 matched non-IBD controls with CAD were included. Patients with IBD were younger (65.3 ± 10.0 versus 67.8 ± 11.0 yr, P = 0.016), had lower prevalence of active tobacco use (10.7% versus 18.7%, P = 0.03), and had lower body mass index (28.0 ± 5.1 versus 29.4 ± 6.4, P = 0.026) compared with controls. Patients with IBD had lower rates of severe left anterior descending artery disease (56% versus 73%, P < 0.0002) and multivessel CAD (71% versus 79%, P = 0.05). There was no difference in post-PCI major adverse cardiovascular outcomes (defined as all-cause death, myocardial infarction, cerebrovascular events, and target lesion revascularization).
CONCLUSIONS: Patients with IBD are diagnosed with CAD at a younger age as compared with non-IBD patients, are less likely to be active smokers and have lower body mass index. Post-PCI outcomes in patients with IBD with CAD are similar to non-IBD controls with CAD.

Entities:  

Mesh:

Year:  2014        PMID: 25105946     DOI: 10.1097/MIB.0000000000000109

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  11 in total

1.  Persistent Reactive Thrombocytosis May Increase the Risk of Coronary Artery Disease Among Inflammatory Bowel Disease Patients.

Authors:  Sudeep Dhoj Thapa; Hiba Hadid; Waseem Imam; Ahmad Hassan; Muhammad Usman; Syed-Mohammed Jafri; Jason Schairer
Journal:  Dig Dis Sci       Date:  2015-05-14       Impact factor: 3.199

2.  Preclinical atherosclerosis in patients with inflammatory bowel diseases: a case-control study.

Authors:  Vincenzo Bruzzese; Giuseppe Palermo; Lorenzo Ridola; Roberto Lorenzetti; Cesare Hassan; Annamaria Izzo; Angelo Zullo
Journal:  Ann Transl Med       Date:  2017-04

Review 3.  Epidemiology, risk factors and management of cardiovascular diseases in IBD.

Authors:  Siddharth Singh; Iftikhar J Kullo; Darrell S Pardi; Edward V Loftus
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2014-12-02       Impact factor: 46.802

4.  International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease.

Authors:  Pablo A Olivera; Stephane Zuily; Paulo G Kotze; Veronique Regnault; Sameer Al Awadhi; Peter Bossuyt; Richard B Gearry; Subrata Ghosh; Taku Kobayashi; Patrick Lacolley; Edouard Louis; Fernando Magro; Siew C Ng; Alfredo Papa; Tim Raine; Fabio V Teixeira; David T Rubin; Silvio Danese; Laurent Peyrin-Biroulet
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-08-27       Impact factor: 46.802

Review 5.  Cardiovascular involvement in inflammatory bowel disease: Dangerous liaisons.

Authors:  Ana Maria Filimon; Lucian Negreanu; Michelle Doca; Andreea Ciobanu; Carmen Monica Preda; Dragos Vinereanu
Journal:  World J Gastroenterol       Date:  2015-09-07       Impact factor: 5.742

6.  Hospitalizations for Acute Myocardial Infarction Are Decreased Among Patients with Inflammatory Bowel Disease Using a Nationwide Inpatient Database.

Authors:  Edward L Barnes; Renee M Beery; Allison R Schulman; Ellen P McCarthy; Joshua R Korzenik; Rachel W Winter
Journal:  Inflamm Bowel Dis       Date:  2016-09       Impact factor: 5.325

7.  The 5A apolipoprotein A-I (apoA-I) mimetic peptide ameliorates experimental colitis by regulating monocyte infiltration.

Authors:  Tobias M Nowacki; Alan T Remaley; Dominik Bettenworth; Michel Eisenblätter; Thorsten Vowinkel; Felix Becker; Thomas Vogl; Johannes Roth; Uwe J Tietge; Andreas Lügering; Jan Heidemann; Jerzy-Roch Nofer
Journal:  Br J Pharmacol       Date:  2016-08-11       Impact factor: 8.739

Review 8.  Endothelial dysfunction in inflammatory bowel diseases: Pathogenesis, assessment and implications.

Authors:  Dorota Cibor; Renata Domagala-Rodacka; Tomasz Rodacki; Artur Jurczyszyn; Tomasz Mach; Danuta Owczarek
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

Review 9.  Preventive health measures in inflammatory bowel disease.

Authors:  Ayokunle T Abegunde; Bashir H Muhammad; Tauseef Ali
Journal:  World J Gastroenterol       Date:  2016-09-14       Impact factor: 5.742

10.  Prevalence of cardiovascular risk factors in a nationally representative adult population with inflammatory bowel disease without atherosclerotic cardiovascular disease.

Authors:  Tanushree Agrawal; Isaac Acquah; Amit K Dey; Kerri Glassner; Bincy Abraham; Ron Blankstein; Salim S Virani; Michael J Blaha; Javier Valero-Elizondo; Nehal Mehta; Eamonn Mm Quigley; Miguel Cainzos-Achirica; Khurram Nasir
Journal:  Am J Prev Cardiol       Date:  2021-03-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.